Amphiphilic nanocarrier-induced modulation of PLK1 and miR-34a leads to improved therapeutic response in pancreatic cancer

Gibori, Hadas; Eliyahu, Shay; Krivitsky, Adva; Ben‐Shushan, Dikla; Epshtein, Yana; Tiram, Galia; Blau, Rachel; Ofek, Paula; Lee, Joo Sang; Ruppin, Eytan; Landsman, Limor; Barshack, Iris; Golan, Talia; Merquiol, Emmanuelle; Blum, Galia; Satchi‐Fainaro, Ronit

doi:10.1038/s41467-017-02283-9

Cited by 70 publications

(67 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…167 In addition to using miRNAs to enhance anti-tumor effects, another study reported that the combination of miR-34a and polo like kinase 1 (PLK1) siRNA delivered by biodegradable amphiphilic polyglutamate amine polymer nanocarrier (APA) markedly enhanced anti-tumor effects of miR-34a in the treatment of PC. 168 These studies demonstrated potential clinical applications of miR-34a in the treatment of PC.…”

Section: The Role Of Mir-34a In the Treatment Of Pcmentioning

confidence: 88%

A Systemic Review on the Regulatory Roles of miR-34a in Gastrointestinal Cancer

Kong¹,

Wang²

2020

OTT

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are a class of endogenous non-coding single-stranded small-molecule RNAs that regulate gene expression by repressing target messenger RNA (mRNA) translation or degrading mRNA. miR-34a is one of the most important miRNAs participating in various physiological and pathological processes. miR-34a is abnormally expressed in a variety of tumors. The roles of miR-34a in gastrointestinal cancer (GIC) draw lots of attention. Numerous studies have demonstrated that dysregulated miR-34a is closely related to the proliferation, differentiation, migration, and invasion of tumor cells, as well as the diagnosis, prognosis, treatment, and chemo-resistance of tumors. Thus, we systematically reviewed the abnormal expression and regulatory roles of miR-34a in GICs including esophageal cancer (EC), gastric cancer (GC), colorectal cancer (CRC), hepatocellular carcinoma (HCC), pancreatic cancer (PC), and gallbladder cancer (GBC). It may provide a profile of versatile roles of miR-34a in GICs.

show abstract

Section: The Role Of Mir-34a In the Treatment Of Pcmentioning

confidence: 88%

A Systemic Review on the Regulatory Roles of miR-34a in Gastrointestinal Cancer

Kong¹,

Wang²

2020

OTT

View full text Add to dashboard Cite

show abstract

“…In this section, the data were extracted by reading the full texts of the eight papers selected. [37][38][39][40][41][42][43][44] They investigated the impact and interaction of some different miRNAs on the expression of the MYC gene in PDAC. The extracted data were collected by two of the authors and were inserted into the extraction form.…”

Section: Data Extractionmentioning

confidence: 99%

MicroRNAs Targeting MYC Expression: Trace of Hope for Pancreatic Cancer Therapy. A Systematic Review

Shams¹,

Aghdaei²,

Behmanesh³

et al. 2020

CMAR

View full text Add to dashboard Cite

Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest malignancies and a major health problem worldwide. There were no major advances in conventional treatments in inhibiting tumor progression and increasing patient survival time. In order to suppress mechanisms responsible for tumor cell development such as those with oncogenic roles, more advanced therapeutic strategies should be sought. One of the most important oncogenes of pancreatic cancer is the MYC gene. The overexpression of MYC can activate many tumorigenic processes such as cell proliferation and pancreatic cancer cell invasion. MiRNAs are important molecules that are confirmed by targeting mRNA transcripts to regulate the expression of the MYC gene. Therefore, restoring MYC-repressing miRNAs expression tends to be an effective method of treating MYC-driven cancers. Objective: The purpose of this study was to identify all validated microRNAs targeting C-MYC expression to inhibit PDAC progression by conducting a systematic review. Methods: In this systematic review study, the papers published between 2000 and 2020 in major online scientific databases including PubMed, Scopus, and Web of Science were screened, following inclusion and exclusion criteria. We extracted all the experimental studies that showed miRNAs could target the expression of the MYC gene in PDAC. Results: Eight papers were selected from a total of 89 papers. We found that six miRNAs (Let-7a, miR-145, miR-34a, miR-375, miR-494, and miR-148a) among the selected studies were validated for targeting MYC gene and three of them confirmed Let-7a as a direct MYC expression regulator in PC cells. Finally, we summarized the latest shreds of evidence of experimentally validated miRNAs targeting the MYC gene with respect to PDAC's therapeutic potential. Conclusion: Restoring the expression of MYC-repressing miRNAs tends to be an effective way to treat MYC-driven cancers such as PDAC. Several miRNAs have been proposed to target this oncogene via bioinformatics tools, but only a few have been experimentally validated for pancreatic cancer cells and models. Further studies should be conducted to find the interaction network of miRNA-MYC to develop more successful therapeutic strategies for PC, using the synergistic effects of these miRNAs.

show abstract

“…Moreover, miR-34 has been shown to be downregulated in pancreatic cancer. The overexpression of miR-34 in these cells increases apoptosis and inhibition of autophagy, reducing tumor growth [44]. Another example is the miR Let-7 family, which targets HRAS and HMGA2 as well as participates in the regulation of proliferation and cell cycle.…”

Section: Micrornas and Cancermentioning

confidence: 99%

A Landscape of Epigenetic Regulation by MicroRNAs to the Hallmarks of Cancer and Cachexia: Implications of Physical Activity to Tumor Regression

Tobias¹,

Gomes²,

Soci³

et al. 2019

Epigenetics

View full text Add to dashboard Cite

In the last decades, there has been a remarkable advance in the treatment of most types of cancer, improving the patient's prognosis. During cancer progression, tumor cells develop several biological changes to support initiation, proliferation, and resistance to death. Nearly 50-80% of all oncologic patients experience rapid weight loss that is related to ~20% of cancer-related deaths. Cancer cachexia is a syndrome characterized by loss of skeletal muscle mass, anorexia, and anemia. A lot of effort in scientific investigation has contributed to the understanding of cancer processes, in which epigenetic changes, as microRNAs, can influence cancer progression. Therefore, useful strategies to control the cancer-induced epigenetic changes in the tumor cells can have a key role in a clinical perspective to decrease the cancer development and aggressiveness. Physical activity has been proposed as a suitable tool to manage tumor growth and cachexia and to improve the deleterious sequelae experienced during cancer treatment. Although the molecular mechanisms involved in these responses are poorly understood, this chapter aims to discuss the role of microRNAs in the cancer-induced epigenetic changes and how physical activity could influence the epigenetic control of tumor cells and cachexia and their potential role in clinical applications for cancer.

show abstract

Amphiphilic nanocarrier-induced modulation of PLK1 and miR-34a leads to improved therapeutic response in pancreatic cancer

Cited by 70 publications

References 57 publications

<p>A Systemic Review on the Regulatory Roles of miR-34a in Gastrointestinal Cancer</p>

<p>A Systemic Review on the Regulatory Roles of miR-34a in Gastrointestinal Cancer</p>

<p>MicroRNAs Targeting MYC Expression: Trace of Hope for Pancreatic Cancer Therapy. A Systematic Review</p>

A Landscape of Epigenetic Regulation by MicroRNAs to the Hallmarks of Cancer and Cachexia: Implications of Physical Activity to Tumor Regression

Contact Info

Product

Resources

About